Fundraising Fox

Fulcrum Therapeutics

NASDAQ: FULC

Cambridge, US · Founded 2015 · Delaware corporation · 2 known investors

Biotech

Founders & leadership

RG
Robert GouldExecutive

Board

AEAlan Ezekowitz
Alan EzekowitzinBoard directorInvestor at Third Rock Ventures
MLMark Levin
Mark LevininBoard directorRetired Founding Partner at Third Rock Ventures
JG
James GeraghtyBoard director
JC
James CollinsBoard director

Investors · 2

Foresite CapitalWest Hollywood
Third Rock VenturesreportedBoston · $100K – $5Mvia Mark Levin · board

Reported raises · per SEC filings

Form D private placements

$183.2M disclosed across 4 rounds · 2016–2020

▶$68.5MraisedJun 2020 · 13 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Mark LevinDirector
  • James GeraghtyDirector
  • Diego CadavidExecutive Officer
  • Kate HavilandDirector
  • James CollinsDirector
  • Katina DortonDirector
  • Robert GouldExecutive Officer, Director
  • Bryan StuartExecutive Officer
  • Owen WallaceExecutive Officer
  • Alan EzekowitzDirector
Offering amount
$68.5M
Amount sold
$68.5M
Sales commissions
$4.1M
Placement agents
SVB Leerink LLC
First sale
Jun 2020
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$80MraisedSep 2018 · 20 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James GeraghtyDirector
  • Alan EzekowitzDirector
  • Kate HavilandDirector
  • James CollinsDirector
  • Mark LevinDirector
  • James TananbaumDirector
  • Amit HasijaExecutive Officer
  • Robert GouldExecutive Officer, Director
  • Owen WallaceExecutive Officer
Offering amount
$80M
Amount sold
$80M
First sale
Aug 2018
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$29.7MraisedJul 2017 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alan EzekowitzDirector
  • Robert GouldExecutive Officer, Director
  • James GeraghtyDirector
  • James CollinsDirector
  • Mark LevinDirector
Offering amount
$55M
Amount sold
$29.7M
First sale
Jul 2016
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$5MraisedMay 2017 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alan EzekowitzDirector
  • James CollinsDirector
  • Mark LevinDirector
  • Robert GouldExecutive Officer, Director
  • James GeraghtyDirector
Offering amount
$5M
Amount sold
$5M
First sale
Apr 2017
Incorporated
Corporation, Delaware, 2015
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news

Form 8K Fulcrum Therapeutics Inc For: 17 August By Investing.comza.investing.com · Aug 2026Fulcrum Therapeutics to merge with Slate Medicines in $245M deal By Investing.cominvesting.com · Aug 2026Slate uses Fulcrum to vault onto Nasdaq with $245M financing for migraine trialsfiercebiotech.com · Aug 2026What's Going On With Fulcrum Therapeutics Stock Monday? - Fulcrum Therapeutics (NASDAQ:FULC) - Benzingabenzinga.com · Aug 2026Kaplan Fox Launches Securities Probe into Fulcrum Therapeutics Following 51% Stock Plunge After Pociredir Program Haltkalkinemedia.com · Aug 2026

Frequently asked questions

Who are Fulcrum Therapeutics's investors?
Fulcrum Therapeutics's investors include Foresite Capital, Third Rock Ventures.
How much funding has Fulcrum Therapeutics raised?
Fulcrum Therapeutics has disclosed $183.2M raised across 4 rounds.
Where is Fulcrum Therapeutics headquartered?
Fulcrum Therapeutics is headquartered in Cambridge, US.